Chabiotech Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

0.64

EPS

—

Div Yield, %

0.25%

Shrs. gr., 5y

1.75%

Rev. gr., 5y

14.32%

Revenues

953.95b

+12.95%

Net income

-8.43b

L-82.27%

CFO

13.02b

Earnings

Feb 26, 2025

Profile

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare. In addition, the company develops immune cells, such as CBT101 for recurrent glioblastoma and solid cancer, and CBT111 and CAR-NK for solid cancer; and stem cells, including CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for macular degeneration and Stargardt's disease. Further, it offers IVF (fertility) services; cosmetics and cosmetic raw materials; medical devices and supplies; bioinsurance storage; research services; and other services. The company was founded in 2002 and is headquartered in Seoul, South Korea.

URL

https://www.chabio.com/

IPO date

Dec 27, 2005

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title KRW in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY
Title KRW in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues	953,951,423 12.95%	844,582,867 16.10%	727,476,087 9.44%
Cost of revenue	814,905,632	774,198,689	624,852,179
Unusual Expense (Income)
NOPBT	139,045,792	70,384,178	102,623,908
NOPBT Margin	14.58%	8.33%	14.11%
Operating Taxes	8,747,841	(1,643,337)	11,810,930
Tax Rate	6.29%		11.51%
NOPAT	130,297,950	72,027,515	90,812,978
Net income	(8,431,247) -82.27%	(47,542,788) 240.36%	(13,968,474) -25.13%
Dividends	(1,506,858)	(1,231,216)	(4,018,570)
Dividend yield	0.13%	0.17%	0.37%
Proceeds from repurchase of equity	23,631,759	99,653	1,378,314
BB yield	-2.11%	-0.01%	-0.13%
Debt
Debt current	307,890,094	66,058,463	102,636,084
Long-term debt	196,148,339	334,801,266	231,201,013
Deferred revenue	24,768,188	23,575,860	22,481,418
Other long-term liabilities	254,654,772	156,044,580	82,860,957
Net debt	155,156,003	(17,552,919)	(215,585,444)
Cash flow
Cash from operating activities	13,018,245	(22,118,668)	23,015,271
CAPEX	(70,364,519)	(128,871,610)	(115,455,007)
Cash from investing activities	(83,720,547)	(74,587,813)	(64,423,842)
Cash from financing activities	66,369,352	50,424,598	30,213,949
FCF	81,838,014	(60,912,371)	(102,773,296)
Balance
Cash	221,788,943	250,626,674	343,526,986
Long term investments	127,093,486	167,785,975	205,895,556
Excess cash	301,184,858	376,183,505	513,048,737
Stockholders' equity	431,426,035	292,689,241	435,205,170
Invested Capital	1,084,207,262	898,886,725	770,337,941
ROIC	13.14%	8.63%	12.29%
ROCE	10.02%	5.89%	8.44%
EV
Common stock shares outstanding	57,071	56,267	54,502
Price	19,590.00 50.69%	13,000.00 -34.84%	19,950.00 -0.50%
Market cap	1,118,013,681 52.85%	731,467,061 -32.73%	1,087,306,661 3.30%
EV	1,648,156,601	1,074,118,222	1,208,777,611
EBITDA	176,844,867	103,166,299	130,084,161
EV/EBITDA	9.32	10.41	9.29
Interest	2,171,811	20,867,655	14,533,619
Interest/NOPBT	1.56%	29.65%	14.16%